China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I clinical study for its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine, marking a significant step in the development of this important pediatric vaccine. The study has begun with the enrollment of the first subject, indicating progress towards understanding the vaccine’s safety and efficacy.
Haemophilus influenzae type b (Hib) and Its Impact on Children
Haemophilus influenzae, a gram-negative bacterium, is a leading cause of acute lower respiratory tract infections in children. The bacterium is categorized into encapsulated and non-encapsulated types, both capable of causing infections. Hib, one of the six serotypes identified, accounts for approximately 95% of invasive Haemophilus influenzae diseases. The development of a vaccine against Hib is crucial for reducing the incidence of these diseases in children.
Vaccine Development and Expected Outcomes
The vaccine under development by CanSino Biologics is covalently bound to purified Hib capsule polysaccharides and tetanus toxoid protein. In its freeze-dried form, the vaccine is anticipated to stimulate humoral immunity against Hib post-vaccination, offering protection to vaccinated individuals. This approach to vaccine development aims to provide a reliable and effective means of preventing Hib infections.
Combination Vaccine Development
CanSino Biologics is also working on a combination vaccine that includes the Hib vaccine as a component, along with component pertussis. This initiative highlights the company’s commitment to expanding its vaccine portfolio and addressing multiple health concerns through a single vaccination regimen.-Fineline Info & Tech
Leave a Reply